DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.
about
Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.Expression of multidrug resistance proteins in invasive ductal carcinoma of the breastTopo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemiaThe anthracycline antibiotics: antitumor drugs that alter chromatin structure.Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerTopoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
P2860
Q33287099-CD66C91C-3D86-4174-BB82-08B530DB2E54Q33480671-EE323ACC-B039-4501-82DE-2A7F768ADB8CQ34293229-40663FBA-975E-4473-B0E3-0F5DB4AA086EQ34433737-E0F56153-CEE3-436E-A98A-861DF5955237Q34555411-D5AFF80A-4395-4F0F-994D-F6F5BEF61043Q35371337-33B7AD8D-13DB-4C65-B29B-F3C544B78193Q35770181-C4C04301-E1AD-4CB4-8F30-DC50D3AC702DQ35925051-D762C6A4-6DFD-4C1F-98F9-47123CC02672Q35990443-1B8200E7-D2EC-4F28-BB6F-26FE5F1AC5A7Q36175746-C35AFB71-45F1-49FB-B4E5-358FC4100959Q36615792-13FE6607-24BC-4AAB-BC82-83210DD60F4EQ36897329-DC1F6C5C-421D-4E96-8A2B-E365D2E19A48Q37355439-57698A96-9DA8-4CFB-81E2-6E04002DDF10Q37937579-AE5F6146-211D-4069-AF48-4D75322B3680Q42117291-9ED01E3D-E8D7-4249-A474-29278E07B6D5Q54376091-6DBF05FD-FDF9-4822-82FD-5596AAC6D34F
P2860
DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@ast
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@en
type
label
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@ast
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@en
prefLabel
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@ast
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@en
P2093
P2860
P356
P1476
DNA topoisomerase IIalpha expr ...... chemotherapy in breast cancer.
@en
P2093
G MacGrogan
G Sierankowski
I de Mascarel Id
J M Coindre
J M Dilhuydy
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601185
P407
P577
2003-08-01T00:00:00Z